Genmab (GMAB) Receives a Hold from Morgan Stanley
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab (GMAB) with a $33 price target. This follows a recent Buy upgrade from TD Cowen, though TD Cowen also issued a separate Hold rating on July 13. Frommer, a 4-star analyst covering healthcare stocks, has a 55.33% success rate.
Morgan Stanley analyst Judah Frommer assigned a Hold rating to Genmab today and set a price target of $33.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Frommer is a 4-star analyst with an average return of 4.6% and a 55.33% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Incyte, Kymera Therapeutics, and Celldex.
In addition to Morgan Stanley, Genmab also received a Hold from TD Cowen’s Yaron Werber in a report issued on July 13. However, yesterday, TD Cowen upgraded Genmab (NASDAQ: GMAB) to a Buy.